The megakaryopoietic potential in the bone marrow (BM) of patients in first remission after treatment for acute myelogenous leukaemia (AML) was investigated using long-term bone marrow cultures (LTC) stimulated with megakaryocyte growth and development factor (MGDF). The baseline number of megakaryocyte colony-forming cells (Meg-CFC) was very low. However, there was a 10 to 100-fold increase of Meg-CFC in cultures treated with 10 ng/ml MGDF with mean numbers within the normal range for the first 4 weeks of culture with a 24-fold increase in their cumulative numbers. Similarly, a 12-fold increase in the numbers of megakaryocytes (MKs) was found by CD61 immunostaining. These effects were lost at the dose of 100 ng/ml. In contrast, the cumulative mean numbers of Meg-CFC in the control cultures from normal bone marrow (NBM) were not significantly different from those in cultures treated with 10 or 100 ng/ml MGDF. These results demonstrate that MGDF stimulates megakaryocytopoiesis in patients with AML in first remission, restoring the Meg-CFC compartment to normal values, a result with potential clinical implications for their treatment with autologous transplantation.
Introduction
Megakaryocyte growth and development factor (MGDF) or thrombopoietin, the ligand of the c-mpl receptor, has been purified and cloned by several groups independently. [1] [2] [3] [4] [5] [6] MGDF has potent effects on the generation, proliferation and differentiation of megakaryocyte (MK) progenitor cells in vitro and in vivo. [7] [8] [9] [10] Patients treated for acute myelogenous leukemia (AML) who achieved first remission show severe and persistent haematopoietic damage manifested by substantially decreased numbers of clonogenic progenitor cells and of stem cells. 11 AML patients in first or subsequent remissions may be treated with autologous transplantation following high-dose chemotherapy. 12, 13 Severe and prolonged thrombocytopenia is usually observed after this treatment.
The effect of MGDF on long-term cultures (LTC) derived from patients with AML in first complete remission was investigated in order to assess their megakaryopoietic potential and response to stimulation. The results indicate that MGDF has the ability to increase the numbers of MK progenitors (Meg-CFC) and CD61
+ cells from a very low baseline to within normal values. 
Materials and methods

Patients
BM samples were collected with informed consent from 13 patients with AML in first complete remission. Patients' characteristics are shown in Table 1 .
As induction and consolidation treatment patients received two to three cycles of DAT chemotherapy, containing daunorubicin (60 mg/m 2 i.v. days 1-3), cytosine arabinoside (200 mg/m 2 continuous infusion, days 1-7) and thioguanin (200 mg/m 2 , days 1-7), followed by up to two cycles of intermediate dose cytosine arabinoside (1.5 g/m 2 at 12 h intervals, days 1-3). Two patients also received high-dose busulfan (16 mg/kg body weight) with peripheral blood progenitor cell rescue prior to the collection of the bone marrow sample, and one patient an allogenic BM transplantation.
Long-term cultures (LTC)
BM samples were obtained after informed consent from healthy donors (NBM) for BM transplantation or AML patients (AMLBM). Cells were separated from the red cells by gravity sedimentation in 0.1% methylcellulose for 45-60 min at room temperature, and washed twice in Iscove's modified Dulbecco's medium (IMDM, Gibco BRL) plus 2% fetal calf serum (FCS, Gibco BRL, Life Technologies, Paisley, UK). 1.5-2 × 10 6 buffy coat cells/ml diluted in 10 ml LTC medium that contained 80% IMDM, 10% FCS, 10% horse serum (HS, Sera Laboratories, Crawley Down, UK), and 5 × 10 −7 M hydrocortisone were inoculated into tissue culture flasks (Falcon, Becton Dickinson, Franklin Lakes, NJ, USA), gassed with 5% CO 2 in air and incubated at 33°C.
14 Rh MGDF (a gift from Amgen Corporation, Thousand Oaks, CA, USA) was added to the LTC at two concentrations, 10 or 100 ng/ml. The cultures were maintained by weekly feeding replacing half of the growth medium with fresh medium and MGDF; control cultures without MGDF were performed concurrently. The non-adherent cells removed at feeding were used for the assays described below.
Clonogenic assays
Cells (10 5 ) were plated in a mixture containing 30% FCS, 1% deionized bovine serum albumin (BSA), 10% conditioned medium from the bladder carcinoma cell line 5637 (as a source of growth factors), 2 U erythropoietin (Boehringer Mannheim, West Lothian, UK) and 1.35% methylcellulose (Sigma, St Louis, MO, USA). Cultures were plated in triplicate and incubated at 37°C for 14 days in a fully humidified atmosphere of 5% CO 2 , 5% O 2 in nitrogen. Colonies consisting of 50 translucent cells or more were counted as GM-CFCderived colonies using an inverted microscope.
To assay Meg-CFC 1-2 × 10 5 cells were plated in a mixture of 30% pretested human aplastic anaemia serum, 5 × 10
2-mercaptoethanol, 5% conditioned medium from phytohaemagglutinin-stimulated leukocytes (PHA-LCM) and 1.35% methylcellulose. Cultures were plated and incubated as described above. We used the established criteria for defining MK colonies: colonies of at least five conspicuously large cells with translucent 'crystal' clear cytoplasm and a well-delineated cell border of high refractility were scored as Meg-CFC.
14 Their megakaryocytic nature was confirmed by picking some colonies for CD61 immunostaining. All results were calculated as total colony-forming cells in the supernatant (SN) per culture; the data in Figures 1-3 are expressed as mean ± s.e.m.
Cell morphology
Cytospins were prepared with 5 × 10 4 cells for Pappenheim stain and CD61 immunostaining (DAKO, Glostrup, Denmark) as previously described, 15 to determine the number of megakaryocytic cells.
Statistics
Formal statistical analysis was confined to the MK profiles. It was felt that the cumulative output in weeks 1-4 captured the aspect of primary interest as it encloses the time of acute regeneration after chemotherapy and also covers the time previously used for autologous transplants with cultured AMLBM cells. 16 On occasion, however, when data were missing for some of the weeks, the observed cumulative output continued to be right censored for such individuals (ie it is assumed that the actual output is known only to be larger than that observed). Right censored data may be analysed with 'survival' methods. The statistical analysis was done with a Cox regression model with appropriate adjustment for the correlation of repeated observations for the same individual. 17 All tests performed in this framework were Wald type tests.
Results
In NBM cultures, Meg-CFC were detected for 7 weeks. However, they were detected only until week 5 in the cultures from patients with AML ( Figure 1 ). In those cultures only very
Figure 1
The upper panel shows the numbers of Meg-CFCs per culture in the supernatant of AML for untreated control cultures (í, n = 13), or treated with 10 ng/ml (b, n = 8) or 100 ng/ml MGDF (̆, n = 7). The lower panel shows data from NBM cultures for untreated (n = 13), or treated with 10 ng/ml (n = 6) or 100 ng/ml MGDF (n = 9). Data are expressed as mean numbers of Meg-CFC ± s.e.m.
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low levels of Meg-CFC were seen during the first 4 weeks of culture. The output of Meg-CFC in untreated AML cultures was at least one log lower than in NBM cultures (P = 0.001). CD61 immunostaining indicated the presence of MK until week 3 for both NBM and AMLBM. However, treatment of AML cultures with MGDF resulted in a two log increment in week 1 and a one log increase in week 2, reaching similar Meg-CFC numbers to those observed in NBM cultures. In these and following experiments, patient 12, who received an allogenic bone marrow transplantation, showed similar results as the rest of the patients, so the results were analysed together. There were no MK colonies detected in clonogenic assays performed from the adherent cells from NBM (n = 4) and AMLBM treated with 10 ng/ml TPO (n = 4) after week 5 of culture.
Analysis of these results showed that the cumulative output of Meg-CFC in weeks 1-4 ( Figure 2 ) was significantly lower in cultures derived from AMLBM than from NBM (P = 0.01). However, treatment of AML cultures with 10 ng/ml MGDF resulted in a 24.3-fold increase in the cumulative mean number of Meg-CFC at week 4 reaching similar numbers of Meg-CFC as those seen in the NBM cultures (P = 0.21). This enhancement was statistically significant (P Ͻ 0.001). The sig-
Figure 2
Percentage of Meg-CFC above an absolute number of Meg-CFC (x). Data are expressed as cumulative numbers of Meg-CFCs from weeks 1 to 4 in AML cultures (upper panel) and NBM (lower panel) for all experiments, discriminated between control (-), 10 ng/ml MGDF (---), 100 ng/ml MGDF (---). Censored values are marked with ticks. The percentage of Meg-CFC in AMLBM using 10 ng/ml MGDF were significantly different from the values of control cultures and cultures using 100 ng/ml MGDF but not significantly different from cultures derived from NBM. nificance was lost in the cultures treated with 100 ng/ml MGDF (P = 0.19). Treatment of NBM with MGDF had no stimulating effect on the numbers of Meg-CFC (P = 0.21), although there appeared to be a trend towards an increased yield (Figure 1) .
Although the number of experiments using immunostaining with CD61 was smaller similar results were found. In the NBM (n = 8) there was a cumulative mean number of 353 positively stained cells by week 4; this was not different in both treatment groups (290 and 370 for 10 and 100 ng/ml MGDF, respectively). However, in AML cultures (n = 3) the corresponding number was 109 for the control with an increase to 1252 in two experiments treated with 10 ng/ml MGDF. In experiments with NBM (Figure 3a) , or with AMLBM ( Figure  3b) , MGDF had no effect on the number of non-adherent cells, nor on the numbers of GM-CFC up to week 4 of culture. However, in agreement with our previously published data 11 from week 5 onwards the numbers of GM-CFC declined in the AML cultures compared to those derived from NBM. This was not changed by administration of MGDF. Treatment with 10 or 100 ng/ml MGDF had no effect on the erythroid colony formation (data not shown).
Discussion
Patients treated for AML develop severe neutropenia and thrombocytopenia which might cause treatment delay and could lead to fatal infections or bleeding. There is hope that MGDF may act in thrombocytopenia similarly to G-CSF in neutropenia, which decreases the median duration of neutropenia in elderly patients after treatment for AML. 18 However, it is known that the haematopoietic status of AML patients in remission shows a marked and persistent deficiency in primitive haematopoietic cells, both at the level of committed progenitors, and of stem cells. 11 It is therefore important to establish that there are enough residual primitive cells able to respond to megakaryopoietic stimulation in response to the appropriate cytokine. This is also relevant for patients who receive an allogenic bone marrow transplantation (like one of the patients in this series), since it is known that these patients have a long-term deficiency in the numbers of CFC in their BM. 19 In these experiments LTC were used to investigate the effect of MGDF on BM from patients in first complete remission. The results demonstrate a several-fold enhancement of Meg-CFC to numbers within the normal range, as well as a similar increase in CD61-positive cells in LTC treated with MGDF at a dose of 10 ng/ml. However, there was no stimulation of Meg-CFC in NBM above normal ranges. Thrombopoietin is synthesized by BM stromal cells. 20 Although the MGDF levels were not measured in these experiments it is known that the concentrations of MGDF used here were well above the levels measured in LTC 20 and human serum. 21 It appears to be likely that there is a deficiency in the microenvironment in AMLBM while the megakaryopoiesis in cultures derived from NBM may be already maximally stimulated by stromal cells.
MGDF effects appear not to be restricted to megakaryocytopoiesis. Recently, it has been shown that MGDF possesses the ability to enhance erythroid proliferation, 22 and in combination with other cytokines, stimulates the proliferation of granulocytes, macrophages 23 and primitive haematopoietic cells; [24] [25] [26] these effects were not observed using MNC from umbilical cord blood (A Schwarzer, personal communication). Furthermore, in those experiments MGDF
Figure 3
The left panel shows the mean numbers (± s.e.m.) of nucleated cells (top) and of GM-CFCs (bottom) per culture in the supernatant of untreated control cultures of AML patients (í, n = 13), or treated with 10 ng/ml (b, n = 8) or 100 ng/ml MGDF (̆, n = 7). The right panel shows the corresponding data for cultures of NBM for untreated control (n = 13), or treated with 10 ng/m (n = 6) or 100 ng/ml MGDF (n = 9).
had no influence on the number of CFC or of granulopoietic or monocytic cells in the cultures. A similar effect has been noted previously using G-CSF which has only a small and transient stimulatory effect on granulopoiesis in LTC of human BM, 27 perhaps because granulopoietic cell production is already adequately stimulated in this system. No attempts were made in these experiments to optimize the system for erythroid growth. These results are in contrast with the increase in granulopoiesis in LTC of murine BM 23 seen together with stimulation of megakaryopoiesis after treatment with thrombopoietin. The lack of influence of MGDF after 5 weeks of culture to generate Meg-CFC in LTC is likely to be due to the poor status and short life of BM cultures of AML in remission, reported previously 11 and confirmed here. It is known that AML cells may express the c-mpl protooncogene 28 and that recombinant human thrombopoietin may induce proliferation of AML cells in vitro. 29, 30 A similar in vitro stimulating effect of G-CSF (and also of other cytokines) on in vitro proliferation of AML cells has been reported. 31 In spite of this, randomised clinical trials in patients with AML have not detected an effect of G-CSF administration on leukaemic cell growth. 18 Thus, it remains to be determined whether the presence of the c-mpl receptor in AML cells will have any clinical relevance for the administration of MGDF to AML patients.
In summary, the present results indicate that the BM of AML patients have enough potential reserve capacity to be able to respond to stimulation of megakaryopoiesis by MGDF, not only by the expected stimulation of platelet production, but also by correcting the serious defect in the numbers of MK progenitors in BM.
